Biotech

Biotech Matthew Herper

STAT Plus: Delfi Diagnostics announces key data, study design for its liquid biopsy test

Biotech Elaine Chen

STAT Plus: Structure Therapeutics oral GLP-1 drug led to weight loss in two studies

Biotech Adam Feuerstein

STAT Plus: Agios drug reduces blood transfusions in patients with beta-thalassemia, study shows

Biotech Matthew Herper

STAT Plus: ASCO24: AstraZeneca won cancer’s big meeting — again. Will that help it fulfill its $80 billion ambition?

Biotech Jason Mast

STAT Plus: Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial

Biotech Adam Feuerstein

STAT Plus: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug

Biotech Elaine Chen

STAT Plus: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone

Biotech Adam Feuerstein

STAT Plus: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment

Biotech Helen Branswell

STAT Plus: FDA approves Moderna’s RSV vaccine, its second licensed product

The Readout Meghana Keshavan

STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates

Biotech Matthew Herper

STAT Plus: For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Biotech Jonathan Wosen

STAT Plus: Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials

Biotech Jason Mast

STAT Plus: Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial

Adam's Take Adam Feuerstein

STAT Plus: Did Sarepta Therapeutics earn $4 billion from exon-skipping drugs that don’t work?

The Readout Elaine Chen

STAT Plus: Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week

Biotech Adam Feuerstein

STAT Plus: Biohaven protein-degrader drug falls short of investor expectations in early-study test

The Readout Elaine Chen

STAT Plus: Wegovy linked to lower risk of alcohol use disorder in real-world study

The Readout Meghana Keshavan

STAT Plus: Biotech’s most interesting fundraisings from the last week

Biotech Andrew Joseph

STAT Plus: Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials

Biotech Adam Feuerstein

STAT Plus: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer

Biotech Andrew Joseph

STAT Plus: Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug

Biotech Timmy Broderick

STAT Plus: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?

Biotech Jason Mast

STAT Plus: Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial

The Readout Meghana Keshavan

STAT Plus: More tumult at BIO amid the company’s fourth CEO in four years

Biotech Elaine Chen

STAT Plus: Ozempic cut risk of death in diabetes patients with chronic kidney disease

Biotech Angus Chen and Jonathan Wosen

STAT Plus: FDA advisers endorse Guardant Health’s colon cancer screening test

Biotech Allison DeAngelis

STAT Plus: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical

The Readout Elaine Chen

STAT Plus: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu